Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Whether non-bismuth quadruple therapy (concomitant therapy) is more effective than bismuth
quadruple therapy or triple therapy for 14 days remains unknown.
Therefore, we aim to compare the eradication rates and long term re-infection rates of
quadruple therapy for 10 days versus non-bismuth quadruple therapy for 10 days vs. triple
therapy for 14 days.
Methods: This will be a multi-center, open labeled, randomized control trial Patients: H.
pylori infected patients who have willingness to receive eradication therapy
Testing for H. pylori infection Before First Line Ttreatment
(1)Any two positive of rapid urease test, histology, serology and culture or a positive UBT
will be considered as H. pylori infected
After First Line Treatment: C13-Urea breath test will be used to assess the existence of H.
pylori 6-8 weeks after first line therapy.
Long term reinfection: C13- Urea breath test will be used to assess the recurrence of H.
pylori 1 year after eradication therapy